PROTAGENIC THERAPEUTICS INC (PTIX) Stock Income Statement
USA - NASDAQ:PTIX - US74365N3017 - Common Stock
2.03 USD
-0.07 (-3.33%)
2.07 USD
+0.04 (+1.97%)
| TTM (2025-6-30) | 2025 (2024-12-31) | 2024 (2023-12-31) | 2023 (2022-12-31) | 2022 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 6.09M | 5.70M | 4.53M | 3.60M | 4.10M | |||
| Research and Development | 2.54M | 3.94M | 3.32M | 1.60M | 1.10M | |||
| Selling, General, and Administrative Expenses | 3.55M | 1.76M | 1.21M | 2.00M | 3.00M | |||
| Operating Income | -6.09M | -5.70M | -4.53M | -3.60M | -4.10M | |||
| Interest Income/Expense | -2.68M | 95.20K | -473.50K | 0 | -400.00K | |||
| Other Income/Expense | null | null | null | null | null | |||
| Non Recurring Items | null | 80.40K | 80.40K | null | null | |||
| Income Before Taxes | -8.69M | -5.53M | -5.00M | -3.60M | -4.50M | |||
| Income Tax | null | 0 | 0 | 0 | 0 | |||
| Net Income | -8.69M | -5.53M | -5.00M | -3.60M | -4.50M | |||
| EBITDA | -6.09M | -5.65M | -4.50M | undefined | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -9.6129 | -15.7865 | -16.1133 | -11.67 | -17.09 | |||
| Non GAAP EPS | null | null | null | null | null | |||
| Statistics | ||||||||
All data in USD